

Synthesis, Characterization, *In Vitro* And *In Silico* Antimicrobial Screening of A Novel Hydrazone Compound

ABSTRACT

The geometric increase of drug-resistant bacteria pathogens has made urgent the research, development and production of new antibacterial and antifungal compounds, hence the synthesis of this novel compound as a potential antibacterial drug. As hydrazones enhanced generally with thiazoles which are 5-membered ring compound containing active nitrogen and sulphur molecules (C_3H_3NS) have been proven to exhibit strong antibacterial and antifungal activities, in this study, salicylaldehyde -4- thiazoleacetic acid hydrazone(SAFTAHA) compound was synthesized. The novel compound was characterized and subjected to anti-microbial screening. The microbes employed were *staphylococcus aureus*, *Escherichia Coli*, *streptococcus* and *klebsiella aerogene*. The compound was found to be active against *Escherichia coli* as the test result recorded ++ indicating 'very active' unlike the other three microbes which either had + or none. To validate this inhibition of *Escherichia coli* by the novel compound and to detect the active site of their interactions, in silico molecular docking analysis of the novel compound against aminopeptidase N from *E. coli* which is known to promote virulence to the microbe in question was carried out. Six drugs commonly used for the treatment of *E. coli* vis-a-viz, ciprofloxacin, levofloxacin, doxycycline, rifamycin, rifaximin and sulfamethoxazole were subjected to same type of silico studies. The result of the docking indicated that the novel hydrazone compound was more efficient and effective than five of the *E. coli* inhibitory drugs as the novel compound has lower binding energy of -6.6 after the docking, while ciprofloxacin drug is -6.0, doxycycline drug is -6.2, rifamycin drug is -5.2, rifaximin drug is -5.7 and sulfamethoxazole drug is -6.6. The synthesized compound has also better interaction with the active site of the microbe concerned as shown in the images for the interactions as follows:- The newly synthesized compound has 5Hb & 9vdW = 14bonds, ciprofloxacin has 3Hb & 9vdW = 12bonds, doxycycline has 2Hb & 4vdW = 06bonds, rifamycin has 2Hb & 4vdW = 06bonds, rifaximin has 0Hb & 4vdW = 06bonds, sulfamethoxazole has 4Hb & 6vdW = 10bonds. Compounds with lower binding energy and good interactions with the active site of the enzyme prove to be better drugs in pharmacy. Sulfamethoxazole drug which has same binding energy with the novel compound has lower interaction with the active site of the bacterium. Salicylaldehyde -4- thiazoleacetic acid hydrazone could therefore be a potential and better drug for the cure of *E. coli* infection.

Keywords

Escherichia coli, Antimicrobial screening, Molecular docking, Binding affinity, Salicylaldehyde -4- thiazoleacetic acid hydrazone

INTRODUCTION

Generally, acyl hydrazone are compounds that contain the -CNN- group, synthesized generally by eliminating water molecule between hydrazine and any of aldehyde or ketone (carbonyl compound) It could be by the condensation of hydrazide with carbonyl compounds [Bedia KK et al. 2006] Hydrazides are the acylated derivatives of hydrazine [J. Pisk, I. Dilovic et al; 2020].

A great attention is given to hydrazones because of their biological and physiological activities [Asif M et al. 2013]. They generally exhibit very strong antibacterial and antifungal activities.

A good number of researchers are interested in synthesizing variety of acyl hydrazones which are known to associate with antimalarial, antitumour, analgesic, antibacterial, antifungal, antitubercular antihelminthic, anticonvulsant, antimicrobial, antidiabetic and/or anti-inflammatory activities [M. E. Shakhdofa et al, 2017 and Asif M et al 2013]. Examples of such hydrazone include; N- (4-tert-Butylbenzoyl)-2-hydraxynaphthalaldehyde (BBNH) a potent inhibitor of the ribonuclease H (R Nase H) activity of human immunodeficiency virus (HIV)-1 reverse transcriptase (RT). This BBNH binds to the HIV- 1 RT R Nase H active site via coordination to the metal and to amino acid. HIV- 1

RT R Nase H can reasonably be inhibited by N- acylhydrazone and phenylhydrazones.[Y. Jin, Z. Tan et al; 2010]

A Research programme carried out on a series of these acyl hydrazones discovered that they are potentially tridentate ligands.

In addition, hydrazones of thiazoleacetic acid are so enhanced that they are used as monoamine oxidase inhibitors and could be applied for curing psychotic illnesses[Nwabueze JN 1997].

A compound known as acetone[4-(5-nitro-2-furyl)-2-thiazolyl]hydrazone is found to have anti cancer potentials [EmilyS. 2011]

Escherichia coli occur as single and straight rods. This bacteria is mostly responsible for acute urinary tract infection and tract sepsia in human. It causes acute enteritis together with haemorrhagic colitis. Its presence can lead to neonatal meningitis. As this infections grows as a biofilm, it is often present in the environment [C.A Batt (2014) in Encyclopedia of food Microbiology 2nd edition]

Aminopeptidase N is a major metalloprotease which can be located in the small intestine and it participates in the controlled hydrolysis of peptides. That is hydrolysis of proteins, [<https://www.ncbi.nlm.nih.gov>] It belongs to the aminopeptidase class with active region similar to the active region of thermolysin. They are zinc dependent enzymes. They are secreted precisely from the acinar cells of the pancreas. This enzyme is one of the known and attractive targets of *E coli* associated disease George S et al. 2014)

The in vitro microbial screening and in silico analysis of the novel compound; salicylaldehyde -4-thiazoleacetic acid hydrazone was performed in this study The docking was on Aminopeptidase N The Salicylaldehyde -4- thiazoleacetic acid hydrazone was tested for sensitivity using *staphylococcus aureus*, *Escherichia coli*, *streptococcus* and *klebsialla aerogenes* microbes, the novel compound was docked on aminopeptidase N enzyme from *E coli*. The binding energy and mechanism of action was compared with those of seven known drugs for the treatment of *E coli* bacteria in Nigeria.

Aim

The aim of this work is to synthesize and produce from handy chemicals a very less resistant and more efficacious drug for the cure of *E coli*, an infection which is rampant in Nigeria and which is very much a drug-resistant bacteria. The new drug being synthesized from handy materials in Nigeria promises to be cost effective

Materials and Methods

Ethyl-2-amino-4-thiazoleacetate was obtained from Sigma – Aldrich Chemical Company Ltd and used without further purification, while other reagents which include the carbonyl compound-salicylaldehyde together with the solvents used which were ethanol and methanol were from the BDH Chemical Ltd, Pools standard rugs for treatment of *E. coli* in Nigeria which include Ciprofloxacin, levofloxacin, doxycycline, trimethoprim, rifamycin, rifaximin and sulfamethoxazole were bought from Orchard Pharmacy Owerri and Pax Pharmacy Onitsha in Nigeria.

The Infrared spectra of the synthesized compound in Nujol were taken on FTIR-8400S Fourier Transformation Infrared Spectrophotometer and the proton NMR using dimethyl sulfoxide DMSO-d₆ and recorded on a Bruker Avance 400 NMR spectrometer at the National Research Institute for Chemical Technology (NARICT), Zaria, Nigeria.

The antimicrobial screening of the novel compound was carried out at University of Abuja Teaching Hospital and Peak Medical Laboratory, Gwagwalada using nutrient Agar on bacteria *staphylococcus aureus*, *Escherichia Coli*, *Streptococcus* and *Klebsialla aerogenes* obtained from the Teaching hospital.

Preparation of 2-amino-4-thiazoleacetic acid hydrazide (ATAH)

Standard method was used to prepare the hydrazides. 1 mole of ethyl-2-amino-4-thiazoleacetate was reacted with 1 mole of the hydrazine hydrate to give the required hydrazide.

2.50 ml (2.40g; 0.04 moles) of hydrazine hydrate was added to 7.0g (0.040 moles) of ethyl-2-amino-4-thiazoleacetate in 50ml of absolute ethanol. Antibumping granules were added and the mixture was refluxed, on a water bath for six hours in a 100ml round-bottom flask. The mixture was poured into a beaker, left for three days to crystallize, and the crystals formed were filtered and recrystallized from ethanol. The resulting crystals were filtered and dried over silica gel in a vacuum desiccators and weighed (Yield, 4.61g; 65.86%). The crystals obtained were light brown in colour.




Fig 1 a: Structure of the intermediate compound

Preparation of Salicylaldehyde-2-amino-4-thiazoleacetic acid hydrazone (SAFTA)

0.86g, (0.005 mole) of 2-amino-4-thiazoleacetic acid hydrazide (ATAH) was mixed with 0.53ml (0.601g, (0.005 moles) of salicylaldehyde in 50ml ethanol and refluxed for 4 hours in a 150ml round bottom flask on water bath. The solution was left for one day to crystallize. The crystals obtained were filtered and were recrystallized from ethanol. The yellow crystals were then dried in a desiccator over silica gel (Yield,0.97g; 80.78%)




Fig 1 b: Structure of salicylaldehyde-2-amino-4-thiazoleacetic acid hydrazone

Characterization and structure determination of the synthesized compound was done using the FTIR obtained using Nujol disc and proton NMR. Other physical analyses were also carried out to confirm the structure.

In vitro susceptibility testing of the synthesized compound was carried out on four types of microorganisms viz *Staphylococcus aureus*, *Escherichia coli*, *Streptococcus*, *Klebsiella aerogenes*.

Disks were improvised using filter papers. The papers were cut into approximately equal sizes. Then, they were sterilized in the oven at a temperature of 60°C for one hour. Next, the papers were allowed to cool and then they were soaked accordingly into the different solutions of the ligand and the complexes obtained (0.005g/ml ethanol). Drying followed, sterilization in the oven at a temperature of 37°C for 24 hours.

The Petri- dishes containing already gelled nutrient agar were inoculated with some microorganisms-, *staphylococcus aureus*, *Escherichia coli*, *streptococcus*, *klebsiella aerogenes*.

. These Petri-dishes were impregnated with the disks containing the novel. They were arranged radially from the centre of the dishes and incubation was done for 24 hours. The result obtained is shown in table 3

Docking procedure

The energy minimized compounds, (synthesized and the known existing drugs) were subjected to docking analyses on aminopeptidase N from *E coli* so as to predict their various interactions with the main binding sites on this enzyme. The Autodock Vina in Pyrx virtual screening software 20 (version

0.8) was employed for the docking studies [Duru CE et al; 2020] The grid box sizes were x centre: 19.19, y centre: 17.59, z centre: 20.88.

Biovia Discovery studio (Biovia 2020) was used to visualize the molecule-ligand interaction (enzyme-drugs) at the end of the docking process and to understudy the simulations

The binding affinities of the different compounds (drugs) docked on the protein target were obtained and the result organized on an excel spreadsheet [Nwofor CN et al: 2022]. The docking result is seen in table 4

Results and Discussion

The physical analysis; solubility test, conductivity, melting point, colour determination are reported in Table 1

Table 1. Results of physical analysis

Compound	Formular	FM WT	Colour	MPT/DEC	%Yeild	Conductivity $\Omega^{-1} \text{ cm}^3 \text{ mol}^{-1}$
SAFTAH	$\text{C}_{12}\text{H}_{12}\text{N}_4\text{O}_8$	171	Yellow	210°	81	-0.289

Solubility Test

Compounds	Water	Acetone	Ethanol	Methanol
SAFTAH	IS	S	S	S

Key

IS Insoluble

S Soluble

Infrared spectra.

The frequency of absorption obtained from infra red spectra is shown in Table 2 . The band of interest include the $\nu(\text{OH})$ $\nu(\text{NH})$ $\nu(\text{C}=\text{N})$, $\nu(\text{C}=\text{O})$, $\nu(\text{C}=\text{N})$,

Compound	$\nu(\text{OH})$	$\nu(\text{N-H})$	$\nu(\text{C}=\text{O})$	$\Delta \nu(\text{C}=\text{O})$	$\nu(\text{C}=\text{N})$	$\Delta \nu(\text{C}=\text{N})$	$\nu(\text{SO}_4^{2-})$	$\nu(\text{M-N})$
SAFTAH	3788	1750		1589				423

H-NMR Spectrum of the novel compound - SAFTAH

Table 2. Chemical Shift and multiplicity

s/n	Chemical Shift	Multiplicity
5	11.15	Singlet
6	3.76	Singlet
8	10.06	Singlet
10	8.38	Singlet
12	8.23	Singlet
13	7.61	Multiple
14	7.26	Multiple
15	7.50	Multiple
16	6.89	Multiple
17	3.39	Singlet

Table 3. Antimicrobial test result for the compound.

Compound	<i>S. aureus</i>	<i>E. coli-</i>	<i>S. spp</i>	<i>K. genes</i>
SAFTAH	-	++	+	-

KEY

S.aureas= *Staphylococcus aureas*

E.Coli= *Escherichia coli*

S.spp= *Streptococcus species*
K.aerogenes= *Klebsiella aero gene*

Table 4 Docking Result for the new compound and other six known drugs

	Drug / Compound	Lowest binding energy	Interaction with active site
1	Salicylaldehyde-4-thiazoleaceticacid hydrazone	-6.6	5Hb & 9vdW = 14bonds
2	ciprofloxacin	-6.0	3Hb & 9vdW = 12bonds
3	doxycycline	-6.2	2Hb & 4vdW = 06bonds
4	rifamycin	-5.2	2Hb & 4vdW = 06bonds
5	rifaximin	-5.7	0Hb & 4vdW = 06bonds
6	sulfamethoxazole	-6.6	4Hb & 6vdW = 10bonds

Key

Hb ----- Hydrogen Bond (Hydrogen bond being the most important in docking interactions)
vdW ---van der Waals

The *Ecoli* Enzyme and the various Interractions with its Key Active Regions




Fig. 2. Aminopeptidase N enzyme from *E coli*




Fig. 3. The 2D interaction of SAFTAH with the active sites of the enzyme from *E. coli*




Fig. 4 The 2D interaction of Ciprofloxacin drug with the enzyme from *E. coli*




Fig. 5. The 2D interaction of Doxycycline drug with the enzyme from *E coli*




Fig. 6. The 2D interaction of Rifamycin drug with the enzyme from *E coli*




Fig. 7. The 2D interaction of Rifaximin drug with the enzyme from *E coli*




Fig.8. The 2D interaction of Sulfamethoxazole drug with the enzyme from *E coli*




Fig. 9. The 2D interaction of Cocrystallized ligand with the enzyme from *E coli*

The compound obtained was active against *E. coli* used for the screening and in silico, the interaction of the novel compound with the aminopeptidase N enzyme is very positive. Therefore, the activity profile of the novel compound indicates the existence of a very significant correlation between the screening and the computational data studies. Moreover, in its interaction with the bacteria, It competes and surpasses five (5) of the commonest known drugs for the treatment of patients suffering from *E coli* in Nigeria. This is so because the novel compound binds better than these drugs at the active sites of the protein, The binding energy of the novel compound is appreciably lower than those of the known drugs as follows; Binding energy of the novel compound -6.6, while ciprofloxacin drug is -6.0, doxycycline drug is -6.2, rifamycin drug is -5.2, rifaximin drug is -5.7 and sulfamethoxazole drug is -6.6. Interaction with the active site of the *E coli* is as follows; the new compound is 5Hb & 9vdW = 14bonds, ciprofloxacin is 3Hb & 9vdW = 12bonds, doxycycline is 2Hb & 4vdW = 06bonds, rifamycin is 2Hb & 4vdW = 06bonds, rifaximin is 0Hb & 4vdW = 06bonds, sulfamethoxazole is 4Hb & 6vdW = 10bonds. This proves that the synthesized compound interacted better with the active site of the *E coli*

It follows then that the newly synthesized compound thiazole compound Salicylaldehyde-2-amino-4-thiazoleacetic acid hydrazone performs better than these known drugs. Even the sulfamethoxazole drug which has same binding energy with the novel compound, fell below it considering the interaction ability with the *E coli*. with 4Hb & 6vdW = 10bonds as against 5Hb & 9vdW = 14bonds of the novel compound. When the interaction is high, the inhibition of the enzyme increases and therefore have better curative effect.

Conclusion

Considering the success recorded - both *in vitro* and *in silico* analyses of this novel compound synthesized, salicylaldehyde-2-amino-4-thiazoleacetic acid hydrazone (SAFTA) emerges as an

excellent potential and more effective drug for the cure of *Escherichia coli* infection in Nigeria, given its in vitro 'very active' inhibitory property with the *E coli* enzyme of double plus (++), its lower binding energy in silico, of -6.6 and better interaction with the active site of the enzyme of 5Hb & 9vdW = 14bonds, when compared with other known drugs for the treatment of the disease in Nigeria. Synthesis of the compound is not difficult and so can be very handy for the treatment of the *E coli* infection which appears to be incessant in Nigeria. The cure therefore promises to be more stable and permanent other than what obtains currently, considering this low binding energy of interaction and the attack on the active site of the disease.

Recommendation

Reacting this novel hydrazone compound with some other carbonyl compounds and subjecting salicylaldehyde into reactions with different hydrazides, all for comparative studies would make a good research and offer proof of whether or not the salicylaldehyde is more efficacious than other carbonyl compounds and whether the novel hydrazone compound possesses more *e coli* treatment ability than other hydrazides

REFERENCES

1. Bedia KK et al. Synthesis and characterization of novel hydrazone-hydrazones and the study of their structure – antituberculosis activity. *European Journal of Medicinal Chemistry*. 2006; 41 (11): 1253-1245
2. Pisk J, Dilovic L et al. Effective methods for the synthesis of hydrazones, quinazolines and Schiff bases: Reaction monitoring using a chemometric approach. *Royal Society of Chemistry Advances*. 2020; (10): 38566-38567.
3. Shakhdofa ME et al. Homotrimetallic transition metal complexes of 2-hydroxy-N¹, N², N³-triphenylpropane-1,2,3-tricarbonylhydrazide preparation and microbe activities. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*. 2017; 8 (2): 724
4. Asif M and Husain A. Analgesic, anti-inflammatory and antiplatelet profile of Hydrazones containing synthetic molecules. *Journal of Applied Chemistry, Hindawi, India*. 2013
5. Jin Y, Tan Z et al. SAR and Molecular mechanism study of novel acylhydrazone compounds targeting HIV-1 C A. *Journal of Bioorganic and Medicinal Chemistry*. 2010; 8 (6): 2135-2136
6. Aggarwal RC, Singh NK and Prasad (Unpublished work)
7. Nwabueze JN. Complexes of Copper (II) with Acetone Hydrazones derived from some cyclohexanecarboxylic acids. *Synth. React. Inorg. met.-Org. Chem*. 1997; 27: 673
8. Emily S. Hospital Epidemiology and infection Control in acute-care setting. *Clinical Microbiology Reviews*. 2011; 24 (1): 141–173.
9. Batt CA. *Encyclopedia of food Microbiology* 2nd edition. 2014.
10. <https://www.ncbi.nlm.nih.gov>
11. Funke T. *Case. Microbiology, An Introduction* 10th Edition. Pearson Benjamin Cummings. 2004,2007,2010.
12. George S et al, Design, docking, synthesis and anti *E coli* screening of novel thiazole thiourea derivatives as possible inhibitors of enoyl reductase (fabI) enzyme. *Bangladesh J. Pharmacol. India*. 2014; 9: 49-53.
13. Duru CE, Duru IA and Bilar A. Computational investigation of sugar fermentation inhibition by berginin at the pyruvate decarboxylase isoenzyme 1 target of *Scharyomyces cervisiae*. *J. Med. Plants Stud*. 2020; 8(6): 21-25
14. Nwofor CN, Duru CE and Onyenwe NE. Computational identification of small molecules in *Mitracarpus scaber* ethanolic leaf extract with fungal keratinase inhibitory potentials. *Journal of Natural Pesticide Research, Elsevier*. 2022; 2:

UNDER PEER REVIEW